Miromatrix Medical Inc. – NASDAQ:MIRO
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Miromatrix Medical stock price monthly change
+0.30%
month
Miromatrix Medical stock price quarterly change
+158.78%
quarter
Miromatrix Medical stock price yearly change
-17.32%
year
Miromatrix Medical key metrics
Market Cap | 92.95M |
Enterprise value | N/A |
P/E | -1.05 |
EV/Sales | -216.14 |
EV/EBITDA | 0.19 |
Price/Sales | 1.54 |
Price/Book | N/A |
PEG ratio | 0.29 |
EPS | -1.13 |
Revenue | 958.02K |
EBITDA | -26.78M |
Income | -27.12M |
Revenue Q/Q | -9.83% |
Revenue Y/Y | 2978.99% |
Profit margin | -114585.35% |
Oper. margin | -114825.89% |
Gross margin | -1767.16% |
EBIT margin | -114825.89% |
EBITDA margin | -2795.98% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMiromatrix Medical stock price history
Miromatrix Medical stock forecast
Miromatrix Medical financial statements
| Dec 2022 | 930.35K | -6.94M | -746.62% |
|---|---|---|---|
| Mar 2023 | 7.98K | -7.19M | -90091.77% |
| Jun 2023 | 8.51K | -6.53M | -76675.12% |
| Sep 2023 | 11.17K | -6.45M | -57745.98% |
| 2025 | 13.5K | -54.97M | -407225.93% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2023-11-14 | -0.18 | -0.24 |
|---|
| Dec 2022 | 34762930 | 8.65M | 24.9% |
|---|---|---|---|
| Mar 2023 | 34242069 | 6.44M | 18.81% |
| Jun 2023 | 28451167 | 6.90M | 24.26% |
| Sep 2023 | 23421149 | 7.87M | 33.64% |
| Dec 2022 | -6.05M | 5.79M | -67.48K |
|---|---|---|---|
| Mar 2023 | -8.61M | 7.98M | 9.04M |
| Jun 2023 | -5.06M | -3.75M | -220.76K |
| Sep 2023 | -4.57M | 6M | 115.81K |
Miromatrix Medical alternative data
| Aug 2023 | 76 |
|---|---|
| Sep 2023 | 76 |
| Oct 2023 | 76 |
| Nov 2023 | 76 |
| Dec 2023 | 76 |
| Jan 2024 | 76 |
| Feb 2024 | 76 |
| Mar 2024 | 76 |
| Apr 2024 | 76 |
| May 2024 | 76 |
| Jun 2024 | 76 |
| Jul 2024 | 76 |
Miromatrix Medical other data
15.94%
-2.00%
of MIRO is owned by hedge funds
3.30M
-444.43K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2023 | 225000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | DOUGLAS JAMES MICHAEL officer: CHIEF FINANCIAL OFFICER | Common Stock | 31,250 | $1.6 | $50,000 | ||
Purchase | BARRY JOHN JOSEPH officer: VICE PRESIDENT OF R&D | Common Stock | 6,250 | $1.6 | $10,000 | ||
Purchase | BUCKMAN PAUL director | Common Stock | 31,250 | $1.6 | $50,000 | ||
Purchase | MAAG PETER director | Common Stock | 31,250 | $1.6 | $50,000 | ||
Purchase | ERB JOHN L director | Common Stock | 31,250 | $1.6 | $50,000 | ||
Purchase | BURKE WILLIAM P. MR. director | Common Stock | 31,250 | $1.6 | $50,000 | ||
Purchase | HEINE LISA WIPPERMAN director | Common Stock | 31,250 | $1.6 | $50,000 | ||
Purchase | ROSS JEFFREY JAMES director, officer.. | Common Stock | 31,250 | $1.6 | $50,000 | ||
Option | ROSS JEFFREY JAMES director, officer.. | Employee Stock Option (right to buy) | 37,500 | $1.25 | $46,875 | ||
Option | ROSS JEFFREY JAMES director, officer.. | Common Stock | 37,500 | $1.25 | $46,875 |
| Quarter | Transcript |
|---|---|
| Q2 2023 19 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 14 May 2023 | Q1 2023 Earnings Call Transcript |
| Q2 2022 15 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 16 May 2022 | Q1 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Jeffrey James Ross Ph.D. (1976) Chief Executive Officer & Director | $323,490 |
Mr. Brian D. Niebur CPA (1964) Chief Financial Officer & Vice President of Fin. | $178,810 |
-
When is Miromatrix Medical's next earnings date?
Unfortunately, Miromatrix Medical's (MIRO) next earnings date is currently unknown.
-
Does Miromatrix Medical pay dividends?
No, Miromatrix Medical does not pay dividends.
-
How much money does Miromatrix Medical make?
Miromatrix Medical has a market capitalization of 92.95M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 2783.54% to 953.47K US dollars. Miromatrix Medical made a loss 30.01M US dollars in net income (profit) last year or -$0.24 on an earnings per share basis.
-
What is Miromatrix Medical's stock symbol?
Miromatrix Medical Inc. is traded on the NASDAQ under the ticker symbol "MIRO".
-
What is Miromatrix Medical's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Miromatrix Medical?
Shares of Miromatrix Medical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Miromatrix Medical's key executives?
Miromatrix Medical's management team includes the following people:
- Dr. Jeffrey James Ross Ph.D. Chief Executive Officer & Director(age: 49, pay: $323,490)
- Mr. Brian D. Niebur CPA Chief Financial Officer & Vice President of Fin.(age: 61, pay: $178,810)
-
How many employees does Miromatrix Medical have?
As Jul 2024, Miromatrix Medical employs 76 workers.
-
When Miromatrix Medical went public?
Miromatrix Medical Inc. is publicly traded company for more then 4 years since IPO on 24 Jun 2021.
-
What is Miromatrix Medical's official website?
The official website for Miromatrix Medical is miromatrix.com.
-
Where are Miromatrix Medical's headquarters?
Miromatrix Medical is headquartered at 6455 Flying Cloud Drive, Eden Prairie, MN.
-
How can i contact Miromatrix Medical?
Miromatrix Medical's mailing address is 6455 Flying Cloud Drive, Eden Prairie, MN and company can be reached via phone at +95 2 942 6000.
Miromatrix Medical company profile:
Miromatrix Medical Inc.
miromatrix.comExchange:
NASDAQ
Full time employees:
76
Industry:
Biotechnology
Sector:
Healthcare
Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. The company has collaborations with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.
6455 Flying Cloud Drive
Eden Prairie, MN 55344
Eden Prairie, MN 55344
CIK: 0001527096
ISIN: US60471P1084
CUSIP: 60471P108
